D. Toppmeyer

842 citations
5 papers · 712 · 1 hit paper · h-index 2

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • PARP inhibition in cancer therapy
    • Cancer Cells and Metastasis
    • HER2/EGFR in Cancer Research
    • Breast Cancer Treatment Studies

Papers in

    • Breast Cancer Treatment Studies 2
    • Cancer Genomics and Diagnostics 1
    • Cancer Immunotherapy and Biomarkers 1
    • HER2/EGFR in Cancer Research 1

D. Toppmeyer

4 papers receiving 694 citations

D. Toppmeyer's Hit Papers

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study 2018 · 681 citations
6810+2+5Years since publication200400600

Peers

D. Toppmeyer
Comparison fields: 5 of 41
  • Oncology 460
  • Cancer Research 257
  • Immunology 44
  • Pulmonary and Respiratory Medicine 37
  • Pathology and Forensic Medicine 14
Replace D.W. Cescon with:
D.W. Cescon Canada
Paula Podolski Croatia
Larysa Ryvo Israel
Andrea E. Wahner-Hendrickson United States
Kristiina M. Joensuu Finland
A. Swat Switzerland
Dina Morein Israel
Ghislane Rouas Belgium
Ming‐Liang Jin China
Magdalena Książkiewicz Poland
D. Toppmeyer relative to D.W. Cescon Canada D.W. Cescon's profile →
Citations per field
00.5×1.5×2×2.3×
D.W. Cescon · 1×
Citations per year

Countries citing papers authored by D. Toppmeyer

Since Specialization
Citations

This map shows the geographic impact of D. Toppmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Toppmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Toppmeyer more than expected).

Fields of papers citing papers by D. Toppmeyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Toppmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Toppmeyer. The network helps show where D. Toppmeyer may publish in the future.

Co-authors

The 19 scholars most cited alongside D. Toppmeyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Toppmeyer Line = papers co-authored together D. Toppmeyer links everyone, so they are left out of the graph.

All Works

5 of 5 papers shown
#Work
1
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Hit paper breakdown →
2018681
2 201029
3 20221
4 20231
5 20260

About D. Toppmeyer

D. Toppmeyer is a scholar working on Cancer Research, Oncology, Genetics, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 5 papers that have together received 712 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (2 papers), Cancer Immunotherapy and Biomarkers (1 paper), Cancer Genomics and Diagnostics (1 paper), HER2/EGFR in Cancer Research (1 paper) and BRCA gene mutations in cancer (1 paper). The work is most often cited by research in Oncology (460 citations), Cancer Research (257 citations), Immunology (44 citations), Pulmonary and Respiratory Medicine (37 citations) and Pathology and Forensic Medicine (14 citations). D. Toppmeyer has collaborated with scholars based in United States. Frequent co-authors include Gyan Bhanot, Erhan Bilal, Ming Yao, Vasudeva Ginjala, Gabriela Alexe, Jean A. McDougall, Anya M. Litvak, Nusayba Ali Bagegni, Salma K. Jabbour and Ekaterina V. Kalashnikova. Their work appears in journals such as ESMO Open, Cancer Epidemiology Biomarkers & Prevention, Annals of Oncology and Genes & Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact